WuXi Biologics (Cayman) Inc. provided earnings guidance for the year ended December 31, 2020. For the year, the company is expected that the profit attributable to equity shareholders of the Company for the year ended December 31, 2020 will increase more than 65% compared with the profit attributable to equity shareholders of the company for the corresponding period of last year.